ERS Research Seminar

Lung Cancer Screening: from Trial to Practice

11 – 12 December 2018
Barcelona, Spain

Tuesday, 11 December 2018

08.15 – 08.30 Registration
08.30 – 08.45 Introduction and welcome
Jan van Meerbeeck and Annemie Snoeckx

Session I – Lung cancer screening: what do we know, what don’t we know
Chairs: Guido van Hal

08.45 – 09.15 NELSON: the Trafalgar of lung cancer screening?
Harry De Koning (Netherlands)

09.15 – 09.45 View from the public health bench
- TBC

09.45 – 10.15 General discussion

10.15 – 10.30 Coffee break

10.30 – 11.30: Session II – Break out session 1: define per country or per 2 countries
1: How is screening of cancer in general organized in your country?
2: Who are the stakeholders for lung cancer screening implementation in your country?
3: What are the necessary steps for lung cancer screening implementation in your country?

11.30 – 12.15 Plenary report of break out groups
Chairs: Mina Gaga and Torsten Blum

12.15 – 13.00 Lunch Break

Session III – Implementation in Europe: hurdles and steps
Chairs: John Field and Annemie Snoeckx

13.00 – 13.20 Participation in screening: lessons learned from the past
Guido Van Hal (Belgium)

13.20 – 13.40 Public understanding and informed decision making: keys to a successful screening programme
David Ritchie (Belgium)

13.40 – 14.00 How to best target the hard-to-reach? The UK-experience?
Samantha Quaife (UK)

14.00 – 14.20 The role of patient advocacy groups in implementation
Bert van Herk (Netherlands)

14.20 – 14.45 Where does the EU go from here?
EU commissioner DG Health and Consumer Protection
14.45 – 15.30 General discussion
15.30 – 16.00 Coffee break

Session IV – Risk assessment strategies
Chairs: Harry De Koning and Torsten Blum

16.00 – 16.20 Risk assessment scores: a critical appraisal
Hans-Ulrich Kauczor (Germany)

16.20 – 16.40 Breathomics: an extra nose to detect lung cancer?
Marc van der Schee (Netherlands)

16.40 – 17.00 Blood biomarkers: ready for practice?
John Field (UK)

17.00 – 17.45 Discussion

17.45 – 18.00 Summary of the day / introduction to day 2
Jan van Meerbeeck (Belgium)

Wednesday, 12 December 2018

08.30 – 10.00 Session V – Break out session 2: standardisation

Group 1: Recruitment implementation - Chairs: Richard Booton and Jan van Meerbeeck
Can we define a minimum common risk assessment strategy for Europe?

Group 2: Technical implementation - Chairs Annemie Snoeckx and Hans-Ulrich Kauczor
Can we define a common minimal SOP for nodule handing and follow up?

10.00 – 10.30 Coffee break

10.30 – 11.00 Report from break out groups
Chairs: David Baldwin and Hans-Ulrich Kauczor

Session VI – From trial to practice: concerns of different stakeholders
Chairs: John Field and Hans-Ulrich Kauczor

11.00 – 11.20 How will lung cancer screening impact our daily practice? A radiologist’s view
Annemie Snoeckx (Belgium)

11.20 – 11.40 Artificial Intelligence: an extra clinician we can not ignore
Bram Van Ginneken (Netherlands)

11.40 – 12.00 The surgeon’s point of view
Herbert Decaluwé (Belgium)

12.00 – 12.30 General discussion

12.30 – 13.00 Summing up: remarks, conclusions and action points

13.00 – 14.00 Lunch and farewell

14.00 – 15.00 Private meeting – KOL’s prepare summary of the meeting
Finalizing the ESR-ERS White paper on screening
Finalizing the White paper co-authors